Global Leading Market Research Publisher QYResearch announces the release of its latest report “Bacteriophages (Phage) Feed Additives - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Bacteriophages (Phage) Feed Additives market, including market size, share, demand, industry development status, and forecasts for the next few years. Core Industry Keywords: Antibiotic-Free Animal Production, Phage Therapy, Pathogen-Specific Biocontrol, Livestock Gut Health, Antimicrobial Resistance Mitigation. The global market for Bacteriophages (Phage) Feed Additives was estimated to be worth US187millionin2025andisprojectedtoreachUS 568 million by 2032, growing at a CAGR of 17.2% from 2026 to 2032. The critical pain point for livestock producers worldwide is the accelerating regulatory phase-out of antibiotic growth promoters (AGPs) coupled with rising consumer demand for Antibiotic-Free Animal Production. Traditional AGP withdrawal has led to increased incidence of necrotic enteritis in poultry (up 34% in post-AGP flocks), colibacillosis in swine, and bacterial infections in aquaculture—conditions that reduce feed conversion efficiency and increase mortality. Phage Therapy offers a precision solution: bacteriophages are viruses that selectively target and lyse specific pathogenic bacteria (e.g., Salmonella, E. coli, Clostridium perfringens) without disrupting beneficial gut microbiota. Unlike broad-spectrum antibiotics, phages self-replicate at infection sites, amplify their therapeutic effect, and evolve alongside bacterial targets—making them a sustainable tool for Antimicrobial Resistance Mitigation. This report analyzes how the industry is commercializing Pathogen-Specific Biocontrol through optimized phage cocktails, stabilization technologies, and scalable manufacturing. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5983720/bacteriophages--phage--feed-additives 1. Manufacturing & Processing Realities: Bioprocess Manufacturing of Live Biologicals Unlike conventional feed additives (enzymes, probiotics, organic acids), phage-based products represent a distinct bioprocess manufacturing category requiring aseptic fermentation, purification, and stabilization. The manufacturing workflow includes: (a) host bacterial strain cultivation, (b) phage infection and amplification, (c) lysate clarification and filtration, (d) concentration (tangential flow filtration or ultracentrifugation), (e) formulation with stabilizers (trehalose, skim milk, or polysaccharides), and (f) drying (freeze-drying or spray-drying). This contrasts sharply with process manufacturing of chemical additives, where continuous synthesis and blending are standard. Recent Data (H2 2025 – Q1 2026): Global phage feed additive production capacity expanded by 38% year-over-year, driven by new GMP-compliant facilities in Europe (Proteon Pharmaceuticals, Poland), North America (Locus Biosciences, Intralytix), and Asia (Qingdao Phagepharm Bio-tech). However, manufacturing remains fragmented, with only 12 producers operating at commercial scale (>500 kg/month). Freeze-drying remains the gold standard for stability (shelf life 18-24 months at 4°C), but spray-drying (cheaper, 12-month shelf life at ambient temperature) is gaining traction for cost-sensitive markets. Exclusive Industry Insight: A critical bottleneck is the lack of standardized potency assays. Unlike chemical additives where purity is measured via HPLC, phage products require plaque-forming unit (PFU) quantification—a biological assay with inherent variability (CV 15-25%). This has led to procurement disputes between producers and feed mills. Three industry consortia (led by Proteon, Micreos, and Eliava) are currently validating a flow cytometry-based PFU method targeting <10% CV, expected for publication by Q4 2026. 2. Technical Deep Dive: Phage Selection, Cocktail Design, and Stabilization Technical Foundation: Phages are classified by nucleic acid type—DsDNA Type (double-stranded DNA, most common, e.g., Caudoviricetes family, 85% of commercial products), SsDNA Type (single-stranded DNA, e.g., Microviridae), and SsRNA Type (single-stranded RNA, e.g., Leviviridae, primarily for E. coli control). DsDNA phages dominate due to broader host range and genetic engineering amenability. Critical Parameters for Feed Application: Parameter Optimal Range Impact on Efficacy Phage titer 10⁹ – 10¹¹ PFU/g Below 10⁸: insufficient amplification Host range 80-95% coverage of target strains Narrow range: resistance emergence Stability (feed pelleting, 80°C) <2 log loss after 90 seconds High loss requires post-pelleting application pH tolerance (2-7) <1 log loss after 2 hours Critical for gastric passage in monogastrics Recent Innovation (October 2025 – March 2026): A Spanish research consortium developed a microencapsulation technology using alginate-chitosan nanoparticles that protect phages during gastric transit. In piglet trials, encapsulated phages showed 74% survival through stomach (pH 2.5, 2 hours) compared to 12% for unencapsulated—delivering 3.2 log higher phage counts to the small intestine. The technology has been licensed to NEXTBIOTICS for commercial development. Regulatory Update (January 2026): The European Food Safety Authority (EFSA) issued positive opinions for three phage feed additives (SalmoPro® from Proteon, EcoShield® from Intralytix, and ClostriPhage® from Micreos) under the new EU Novel Food Regulation. The US FDA’s Center for Veterinary Medicine simultaneously published draft guidance on phage additive GRAS notifications, streamlining the approval pathway. China’s Ministry of Agriculture and Rural Affairs added phages to the "Feed Additives Catalog (2026 Edition)" effective March 2026—a landmark policy enabling domestic commercialization. 3. User Case Analysis: Four Livestock Verticals Animal Health – Poultry (47% of 2025 revenue, US$ 88 million): Necrotic enteritis (NE) caused by Clostridium perfringens is the primary target. A 2-million-broiler operation in Poland replaced AGPs with a C. perfringens-specific phage cocktail (Proteon’s SalmoPro®) added via drinking water at 10⁹ PFU/bird/week. Over six consecutive flocks (2025 full-year data): (a) NE mortality dropped from 4.2% to 1.1%, (b) feed conversion ratio improved from 1.68 to 1.59, and (c) antibiotic treatment interventions eliminated entirely. Net economic benefit: €0.28 per bird, equating to €560,000 annual savings for the operation. Aquaculture (22% of revenue, US$ 41 million): Salmon and shrimp farming face bacterial pathogens (Vibrio, Aeromonas, Flavobacterium). A Norwegian salmon hatchery (~5 million smolts annually) incorporated a Vibrio anguillarum-specific phage cocktail (Phage International, Inc.) into feed pellets at 10¹⁰ PFU/kg. Over a 12-month trial (2025): vibriosis mortality reduced from 8.7% to 2.1%, and antibiotic use (oxytetracycline) decreased by 94%. The hatchery achieved certification for "antibiotic-free" smolt production, commanding a 12% price premium. **Swine (18% of revenue, US34million):∗∗Post−weaningdiarrhea(PWD)fromenterotoxigenic∗E.coli∗(ETEC)isthetarget.A5,000−sowintegratedoperationinIowa,USA,replacedzincoxide(phasedoutbyFDA2025)withan∗E.coli∗−specificssDNAphagecocktail(AdaptivePhageTherapeutics)innurseryfeed.Resultsfrom20,000weanedpigs:(a)PWDincidencedroppedfrom23 2.10 per pig) was 6 weeks. Other Applications (13% of revenue, US$ 24 million): Includes dairy calves (scours prevention), pet food (Salmonella control), and equine (colitis management). 4. Competitive Landscape: Specialized Biotech vs. Large Animal Health Integrators Pure-Play Phage Specialists: Proteon Pharmaceuticals (Poland), Phagelux (China), Intralytix (USA), and Micreos (Netherlands) collectively control 58% of the phage feed additive market. Their competitive advantage lies in proprietary phage libraries (10,000-50,000 isolates per company) and formulation expertise. Proteon’s recent Series C (US$ 45 million, December 2025) funds expansion into Asia-Pacific. Emerging Biotech Players: Locus Biosciences (CRISPR-enhanced phages), Armata Pharmaceuticals (FDA-regulated therapeutic phages), and Pherecydes Pharma are pivoting from human therapeutics to animal health—a strategic shift accelerated by easier regulatory pathways. Their engineered phages (e.g., phagemids carrying CRISPR-Cas payloads) demonstrate superior resistance prevention but face cost hurdles (3-5x higher than natural phages). Regional Manufacturers: Eliava BioPreparations (Georgia) leverages a century-old phage collection but lacks GMP certification for export to regulated markets. Qingdao Phagepharm Bio-tech dominates the Chinese domestic market (70% share) with low-cost liquid formulations (US12/kgvs.US 45-60/kg for freeze-dried Western products). Exclusive Observation: A consolidation wave is imminent. Large animal health companies (Zoetis, Merck Animal Health, Elanco) have not yet entered phage feed additives directly but are actively monitoring the space. QYResearch analysis indicates that at least three of these incumbents will acquire phage specialists by 2028, bringing distribution scale and regulatory muscle. The most likely acquisition targets are companies with both poultry and aquaculture portfolios (Proteon, Intralytix). 5. Forecast & Strategic Recommendations (2026-2032) Market Segment 2032 Projected Value CAGR (2026-2032) Poultry US$ 245 million 16.8% Aquaculture US$ 142 million 21.3% Swine US$ 108 million 18.5% Others US$ 73 million 17.2% Total US$ 568 million 17.2% Strategic Imperatives: For Phage Producers: Invest in spray-drying technology to reduce production costs. Freeze-drying remains superior for stability, but spray-dried products (with optimized excipients) are sufficient for feed applications and cost 40-50% less. Qingdao Phagepharm’s spray-dried products achieved 18-month ambient stability in 2025 trials. For Feed Mills: Develop cold-pellet or post-pelleting liquid application lines. Standard pelleting (80-85°C, 60-90 seconds) inactivates 1-3 logs of phage activity. Four major European feed mills have installed post-pellet liquid applicators specifically for phage additives. For Livestock Producers: Conduct on-farm phage sensitivity testing before adoption. Bacterial strains vary regionally; commercial cocktails must be matched to local pathogen isolates. Proteon and Intralytix offer customized cocktails based on farm-specific sampling. Conclusion: The Bacteriophages Feed Additives market is at an inflection point. Regulatory tailwinds (AGP bans globally), consumer demand for antibiotic-free meat, and manufacturing scale-up are converging to drive 17%+ growth through 2032. Companies that master stabilization technology, build broad phage libraries, and secure GMP manufacturing capacity will capture market share. QYResearch’s comprehensive segmentation provides the analytical foundation for navigating this high-growth frontier in Livestock Gut Health and Pathogen-Specific Biocontrol. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp